<DOC>
	<DOC>NCT00259116</DOC>
	<brief_summary>This trial is a single center, open-label, dose-finding study of recombinant human relaxin (rhRlx) given intravenously (IV) to patients with stable, compensated CHF.</brief_summary>
	<brief_title>A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure</brief_title>
	<detailed_description>Serial cohorts of patients with stable CHF will be enrolled upon meeting eligibility criteria. Dose escalation will be guided by hemodynamic response, safety and tolerability. The effects of rhRlx on hemodynamics will be assessed.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Methocarbamol</mesh_term>
	<criteria>Male and female patients over the age of 18 New York Heart Association (NYHA) Class IIIII CHF Left Ventricular Ejection Fraction (LVEF) of &lt; 35% Acute coronary syndrome Acute decompensated CHF Hypotension Recent significant arrhythmia Recent stroke Significant renal or hepatic impairment Pregnancy or childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Congestive heart failure</keyword>
	<keyword>Relaxin</keyword>
	<keyword>Cardiac hemodynamics</keyword>
</DOC>